Testing effectiveness (Phase 2)Ended earlyNCT03827850What this trial is testingFGFR Inhibitor in FGFR Dysregulated CancerWho this might be right forLung CancerNSCLCPulmonary Neoplasm+2 more Lung Cancer Group Cologne 22
Early research (Phase 1)WithdrawnNCT07073183What this trial is testingSafety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)Who this might be right forSquamous NSCLC CureVac
Testing effectiveness (Phase 2)Looking for participantsNCT05613413What this trial is testingA Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)Who this might be right forMetastatic Squamous Non-Small Cell Lung Carcinoma University of Illinois at Chicago 36
Large-scale testing (Phase 3)Looking for participantsNCT07416474What this trial is testingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)Who this might be right forNon-Small Cell Lung Cancer RemeGen Co., Ltd. 574
Testing effectiveness (Phase 2)Looking for participantsNCT05902988What this trial is testingA Phase I/II Study of VLS-1488 in Subjects With Advanced CancerWho this might be right forAdvanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung Cancer+7 more Volastra Therapeutics, Inc. 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03485209What this trial is testingEfficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsWho this might be right forColorectal NeoplasmsCarcinoma, Non-Small-Cell LungExocrine Pancreatic Cancer+1 more Seagen, a wholly owned subsidiary of Pfizer 350
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07742956What this trial is testingPhase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.Who this might be right forNSCLC (Advanced Non-small Cell Lung Cancer) Shanghai Allink Biotherapeutics Co., Ltd. 156
Testing effectiveness (Phase 2)Looking for participantsNCT05910827What this trial is testingA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell CancersWho this might be right forAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Esophageal Squamous Cell Carcinoma+4 more Hummingbird Bioscience 398
Early research (Phase 1)Ended earlyNCT05267470What this trial is testingBemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)Who this might be right forSquamous-Cell Non-Small-Cell Lung Cancer Amgen 74
Testing effectiveness (Phase 2)UnknownNCT04976647What this trial is testingHLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLCWho this might be right forSquamous Non-small-cell Lung Cancer Shanghai Henlius Biotech 156
Large-scale testing (Phase 3)Not Yet RecruitingNCT07318883What this trial is testingA Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerWho this might be right forSquamous NSCLC Shanghai Henlius Biotech 720
Testing effectiveness (Phase 2)Looking for participantsNCT07730021What this trial is testingASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsWho this might be right forLocally Advanced or Metastatic Solid Tumors Astellas Pharma Global Development, Inc. 392
Early research (Phase 1)Study completedNCT01884285What this trial is testingAZD8186 First Time In Patient Ascending Dose StudyWho this might be right forAdvanced Castrate-resistant Prostate Cancer CRPCSquamous Non-Small Cell Lung Cancer sqNSCLCTriple Negative Breast Cancer TNBC AstraZeneca 147
Not applicableNo Longer AvailableNCT02475382What this trial is testingExpanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenWho this might be right forSquamous Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung Cancer Bristol-Myers Squibb
Early research (Phase 1)Not Yet RecruitingNCT07614646What this trial is testingEvaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC PatientsWho this might be right forSquamous Non-Small Cell Lung Cancer sqNSCLC Everest Medicines (Beijing) Co., Ltd. 13
Large-scale testing (Phase 3)Not Yet RecruitingNCT06319313What this trial is testingEfficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerWho this might be right forSquamous Cell Non-small Cell Lung Cancer Shanghai JMT-Bio Inc. 534
Post-approval studies (Phase 4)Looking for participantsNCT07744698What this trial is testingMetronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)Who this might be right forSquamous Non-Small Cell Lung Cancer sqNSCLCExtensive-stage Small Cell Lung Cancer (ES-SCLC) Anhui Provincial Cancer Hospital 107
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06747169What this trial is testingEfficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical StudyWho this might be right forSquamous Non-Small Cell Lung Cancer SqNSCLC Jian-Guo Zhou, MD, PhD 32
Testing effectiveness (Phase 2)Study completedNCT02409368What this trial is testingAn Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCWho this might be right forNon-Small Cell Lung Cancer Bristol-Myers Squibb 812
Testing effectiveness (Phase 2)Ended earlyNCT05275673What this trial is testingSapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung CancerSquamous Non-small-cell Lung CancerSquamous Non-Small Cell Neoplasm of Lung+1 more Faeth Therapeutics 7